Brawn Biotech Limited reported earnings results for the fourth quarter and full year ended March 31, 2024. For the fourth quarter, the company reported sales was INR 34.47 million compared to INR 47.53 million a year ago. Revenue was INR 35.3 million compared to INR 47.56 million a year ago. Net loss was INR 3.42 million compared to INR 6.08 million a year ago. Basic loss per share from continuing operations was INR 1.12 compared to INR 2.03 a year ago. Diluted loss per share from continuing operations was INR 1.12 compared to INR 2.03 a year ago.

For the full year, the company reported sales was INR 164.95 million compared to INR 222.31 million a year ago. Revenue was INR 165.83 million compared to INR 222.4 million a year ago. Net loss was INR 15.44 million compared to INR 8.68 million a year ago. Basic loss per share from continuing operations was INR 5.14 compared to INR 3.04 a year ago. Diluted loss per share from continuing operations was INR 5.14 compared to INR 3.04 a year ago.